There are two kinds of people in the world, says Brent Vaughan — those who prefer to make incremental changes with a lower likelihood of failure, and those who aspire to fix (seemingly) intractable problems that have stymied others. Brent falls in the latter category. A serial entrepreneur, former venture capitalist, and current CEO of Cognito Therapeutics (a DTx company that specializes in neurodegenerative diseases), Brent is also uniquely positioned to evaluate the future of next generation digital therapeutics.

Brent and Eugene talk about the differences between prescription and business-to-consumer DTx, the importance of engaging patients and users early on in the development of novel products, and the exciting potential of translational DTx solutions. Eugene’s podcast partner, Brian Dolan, also pops in with a question.

Guest Links and Resources:

Connect with Brent Vaughan: LinkedIn
Visit Cognito Therapeutics: Twitter | LinkedIn | Facebook | Website

Host Links:

Connect with Eugene Borukhovich: Twitter | LinkedIn
Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn
Connect with YourCoach.health: Website | Twitter
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event

Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:

> Presenting Partner: Amalgam Rx

> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health

Follow Digital Health Today:

Browse Episodes | Twitter | LinkedIn | Facebook | Instagram

Follow Health Podcast Network:

Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Replay: Leveraging Novel Technologies to Meet Unmet Medical Needs

Powered by Wave AI